PharmaCyte Going Head to Head with Eli Lilly's Pancreatic Cancer Drug in New Clinical Trial
24. Januar 2017 09:10 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - January 24, 2017) - Ten years ago the National Cancer Institute (NCI) recognized the rise in pancreatic cancer deaths and called for the development of better treatments....
PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial
12. Dezember 2016 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - December 12, 2016) - All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic...
PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial
01. Dezember 2016 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - December 01, 2016) - PharmaCyte Biotech (OTCQB: PMCB) is now one step closer to enrolling patients in a pivotal clinic trial in advanced, inoperable pancreatic cancer...
PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial
16. November 2016 09:15 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - November 16, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has arrived at the door of U.S. FDA and awaits a pre-IND meeting with the agency. After years of surrounding its...
As Diabetes Becomes Global Epidemic, PharmaCyte Biotech's Insulin Producing Cells Receive 20 Years of Protection
19. Juli 2016 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - July 19, 2016) - Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to...
PharmaCyte Biotech Uses "Artificial Liver" to Treat Advanced Pancreatic Cancer
07. Juli 2016 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - July 07, 2016) - PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, is being used in treatments for both cancer and...
PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial
05. Mai 2016 09:15 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - May 05, 2016) - PharmaCyte Biotech (OTCQB: PMCB) has now reached a point in its life cycle where it is ready to start working with the U.S. FDA to get the company's...
PharmaCyte Biotech's CEO Explains How New Clinical Trial Design Changed the GMP Certification Process
06. April 2016 09:20 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - April 06, 2016) - PharmaCyte Biotech (OTCQB: PMCB) expects to begin its clinical trial in advanced pancreatic cancer in 2016; however, locking down an exact date has...
PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial
15. Oktober 2015 09:25 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - October 15, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) advanced pancreatic cancer treatment of Cell-in-a-Box® capsules + low-doses of ifosfamide has outperformed Eli...
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
09. Oktober 2015 09:25 ET
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - October 09, 2015) - The combination of PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has...